|
PE20150953A1
(es)
*
|
2012-11-08 |
2015-06-20 |
Bristol Myers Squibb Co |
Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
|
|
SG11201503395TA
(en)
|
2012-11-08 |
2015-05-28 |
Bristol Myers Squibb Co |
ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
|
|
EP2922846B1
(en)
*
|
2012-11-08 |
2018-10-03 |
Bristol-Myers Squibb Company |
Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha
|
|
TWI582077B
(zh)
|
2013-11-07 |
2017-05-11 |
必治妥美雅史谷比公司 |
作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
|
|
CN105992768B
(zh)
|
2013-12-10 |
2018-04-20 |
百时美施贵宝公司 |
用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
WO2016001341A1
(en)
*
|
2014-07-03 |
2016-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonylaminopyridine compounds, compositions and methods of use
|
|
WO2016022626A1
(en)
*
|
2014-08-06 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Heterocyclic cgrp receptor antagonists
|
|
AR105113A1
(es)
|
2015-06-24 |
2017-09-06 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituida con heteroarilo
|
|
US10618903B2
(en)
|
2015-06-24 |
2020-04-14 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
UY36747A
(es)
|
2015-06-24 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
|
|
DK3380465T3
(da)
*
|
2015-11-26 |
2020-10-26 |
Novartis Ag |
Diaminopyridinderivativer
|
|
CN115448916A
(zh)
|
2016-10-14 |
2022-12-09 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
AU2017345736B2
(en)
|
2016-10-21 |
2022-04-07 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
|
AR110351A1
(es)
*
|
2016-12-13 |
2019-03-20 |
Bristol Myers Squibb Co |
COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
|
|
CA3055209A1
(en)
|
2017-03-08 |
2018-09-13 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
US10899745B2
(en)
*
|
2017-03-30 |
2021-01-26 |
Bristol-Myers Squibb Company |
Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
|
|
MY200228A
(en)
|
2017-05-11 |
2023-12-15 |
Bristol Myers Squibb Co |
Thienopyridines and benzothiophenes useful as irak4 inhibitors
|
|
TWI776810B
(zh)
*
|
2017-05-12 |
2022-09-11 |
瑞士商諾華公司 |
新穎二胺基吡啶衍生物
|
|
JP7216705B2
(ja)
|
2017-07-28 |
2023-02-02 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用方法
|
|
CA3083122A1
(en)
*
|
2017-11-21 |
2019-05-31 |
Bristol-Myers Squibb Company |
Sulfone pyridine alkyl amide-substituted heteroaryl compounds
|
|
IL315310A
(en)
*
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11685723B2
(en)
|
2018-02-13 |
2023-06-27 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: O-alkyl-deuterated pyronins
|
|
US12209082B2
(en)
|
2018-02-13 |
2025-01-28 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: soluble salts and aqueous formulations of pyronins
|
|
WO2019173507A1
(en)
|
2018-03-06 |
2019-09-12 |
Rutgers, The State University Of New Jersey |
Antibacterial agents : arylalkylcarboxamido phloroglucinols
|
|
AR117398A1
(es)
|
2018-03-12 |
2021-08-04 |
Abbvie Inc |
Inhibidores de la señalización mediada por tirosina cinasa 2
|
|
CN111936486B
(zh)
*
|
2018-03-22 |
2023-09-22 |
百时美施贵宝公司 |
用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11414431B2
(en)
|
2018-10-15 |
2022-08-16 |
Nimbus Lakshmi, Inc. |
Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
|
|
SG11202104307VA
(en)
*
|
2018-10-30 |
2021-05-28 |
Bristol Myers Squibb Co |
Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CA3120866A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
US11174264B2
(en)
|
2019-01-23 |
2021-11-16 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
JP7652697B2
(ja)
*
|
2019-01-28 |
2025-03-27 |
江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 |
ピリダジン系誘導体阻害剤、その製造方法及び使用
|
|
MX2021015995A
(es)
|
2019-06-28 |
2022-03-11 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021011727A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
|
|
WO2021011724A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
JP7573596B2
(ja)
|
2019-07-23 |
2024-10-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
|
|
CN114174279B
(zh)
|
2019-08-06 |
2024-07-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的双环杂环化合物
|
|
US12570659B2
(en)
|
2019-08-13 |
2026-03-10 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl compounds useful as IRAK4 inhibitors
|
|
CN119874700A
(zh)
|
2019-09-13 |
2025-04-25 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN115052627A
(zh)
|
2019-12-17 |
2022-09-13 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
CN115335380B
(zh)
|
2020-02-03 |
2024-08-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的三环杂芳基化合物
|
|
US12391702B2
(en)
|
2020-02-03 |
2025-08-19 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
|
|
US20220330549A1
(en)
*
|
2020-03-11 |
2022-10-20 |
Northwest A&F University |
Use of n-benzylbenzamide-based compound as herbicide
|
|
CA3174845A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Craig Alan Coburn |
Substituted pyridines for the treatment of inflammatory diseases
|
|
US12479831B2
(en)
|
2020-04-28 |
2025-11-25 |
Bristol-Myers Squibb Company |
Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators
|
|
JP7537002B2
(ja)
*
|
2020-08-07 |
2024-08-20 |
南京薬石科技股▲フン▼有限公司 |
Ｃｄｋ９阻害剤およびその使用
|
|
CN114181257B
(zh)
*
|
2020-09-14 |
2025-02-14 |
四川科伦博泰生物医药股份有限公司 |
吡啶类化合物，包含其的药物组合物，其制备方法及其用途
|
|
EP4232425A4
(en)
|
2020-10-23 |
2024-07-24 |
Nimbus Clotho, Inc. |
Ctps1 inhibitors and uses thereof
|
|
WO2022133046A2
(en)
*
|
2020-12-16 |
2022-06-23 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
CA3202360A1
(en)
|
2020-12-30 |
2022-07-07 |
Nello Mainolfi |
Irak degraders and uses thereof
|
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
CN117098757A
(zh)
|
2021-02-02 |
2023-11-21 |
里米诺生物科学有限公司 |
Gpr84拮抗剂和其用途
|
|
US12252488B2
(en)
|
2021-02-12 |
2025-03-18 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
CA3207049A1
(en)
|
2021-02-15 |
2022-08-18 |
Jared Gollob |
Irak4 degraders and uses thereof
|
|
EP4294806A1
(en)
*
|
2021-02-19 |
2023-12-27 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
WO2022175745A1
(en)
*
|
2021-02-19 |
2022-08-25 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
TW202246233A
(zh)
|
2021-02-19 |
2022-12-01 |
英商蘇多生物科學有限公司 |
Tyk2抑制劑及其用途
|
|
TW202246232A
(zh)
*
|
2021-02-19 |
2022-12-01 |
英商蘇多生物科學有限公司 |
Ｔｙｋ２抑制劑及其用途
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
IL308422A
(en)
*
|
2021-05-14 |
2024-01-01 |
Bristol Myers Squibb Co |
substituted heterocyclic compounds
|
|
CA3236262A1
(en)
|
2021-10-25 |
2023-05-04 |
Isaac Marx |
Tyk2 degraders and uses thereof
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
WO2023108536A1
(en)
*
|
2021-12-16 |
2023-06-22 |
Lynk Pharmaceuticals Co. Ltd. |
Tyk2 inhibitors and compositions and methods thereof
|
|
AU2022412835A1
(en)
*
|
2021-12-16 |
2024-06-20 |
Lynk Pharmaceuticals Co. Ltd. |
Tyk2 inhibitors and compositions and methods thereof
|
|
US12091411B2
(en)
|
2022-01-31 |
2024-09-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN116693449A
(zh)
|
2022-03-04 |
2023-09-05 |
上海致根医药科技有限公司 |
用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
|
|
EP4511366A1
(en)
*
|
2022-04-19 |
2025-02-26 |
Blueprint Medicines Corporation |
Kit inhibitors
|
|
WO2023227946A1
(en)
*
|
2022-05-27 |
2023-11-30 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
CN119894873A
(zh)
|
2022-08-02 |
2025-04-25 |
里米诺生物科学有限公司 |
芳基三唑基和相关gpr84拮抗剂及其用途
|
|
KR20250056924A
(ko)
|
2022-08-02 |
2025-04-28 |
리미널 바이오사이언시스 리미티드 |
치환된 피리돈 gpr84 길항제 및 이의 용도
|
|
CN121194786A
(zh)
*
|
2023-06-02 |
2025-12-23 |
Idrx股份有限公司 |
用于治疗癌症的包含kit抑制剂的组合疗法
|
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|